Our top pick for
Soligenix Inc is a biotechnology business based in the US. Soligenix shares (SNGX) are listed on the NASDAQ and all prices are listed in US Dollars. Soligenix employs 17 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.06|
|52-week range||$0.85 - $2.78|
|50-day moving average||$1.06|
|200-day moving average||$1.11|
|Wall St. target price||$4.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.34|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||0.95%|
|1 month (2021-09-20)||3.92%|
|3 months (2021-07-20)||13.98%|
|6 months (2021-04-20)||-17.19%|
|1 year (2020-10-20)||-37.65%|
|2 years (2019-10-18)||20.39%|
|3 years (2018-10-19)||1.27|
|5 years (2016-10-20)||5.08|
|Revenue TTM||$1.3 million|
|Gross profit TTM||$538,498|
|Return on assets TTM||-37.44%|
|Return on equity TTM||-107.18%|
|Market capitalisation||$44.1 million|
TTM: trailing 12 months
There are currently 1.0 million Soligenix shares held short by investors – that's known as Soligenix's "short interest". This figure is 31% down from 1.5 million last month.
There are a few different ways that this level of interest in shorting Soligenix shares can be evaluated.
Soligenix's "short interest ratio" (SIR) is the quantity of Soligenix shares currently shorted divided by the average quantity of Soligenix shares traded daily (recently around 4.0 million). Soligenix's SIR currently stands at 0.26. In other words for every 100,000 Soligenix shares traded daily on the market, roughly 260 shares are currently held short.
However Soligenix's short interest can also be evaluated against the total number of Soligenix shares, or, against the total number of tradable Soligenix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Soligenix's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Soligenix shares in existence, roughly 30 shares are currently held short) or 0.0259% of the tradable shares (for every 100,000 tradable Soligenix shares, roughly 26 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Soligenix.
Find out more about how you can short Soligenix stock.
We're not expecting Soligenix to pay a dividend over the next 12 months.
Soligenix's shares were split on a 1:10 basis on 6 October 2016. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Soligenix shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Soligenix shares which in turn could have impacted Soligenix's share price.
Over the last 12 months, Soligenix's shares have ranged in value from as little as $0.85 up to $2.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Soligenix's is 1.3016. This would suggest that Soligenix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Soligenix, Inc. , a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which has completed Phase I/II clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease and SGX201 for acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.